As­traZeneca, Mer­ck her­ald PhI­II prostate can­cer win for Lyn­parza — over­tak­ing Clo­vis, J&J in PARP race

The case for ex­pand­ing Lyn­parza’s use just got stronger as As­traZeneca and Mer­ck claim a late-stage suc­cess in ex­tend­ing the time prostate can­cer pa­tients live with­out pro­gress­ing com­pared to stan­dard of care.

Ri­vals at Clo­vis pro­vid­ed the first re­sound­ing ev­i­dence that PARP in­hibitors could be pow­er­ful against metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer last Oc­to­ber, when it un­veiled at ES­MO that Rubra­ca in­duced a 44% con­firmed ob­jec­tive re­sponse rate among 25 sec­ond-line pa­tients with a BR­CA al­ter­ation. Days pri­or to the pre­sen­ta­tion, the Phase II da­ta had earned the biotech a “break­through” des­ig­na­tion at the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER